










# Takeda Oncology Pipeline

We are advancing a pipeline of investigational therapies with the highest potential to reach patients. We are currently focused on four core modalities: antibody drug conjugates (ADCs), bispecifics, small molecules and gamma delta T cell therapies. We are evaluating investigational therapies that leverage these modalities in solid tumors - with a focus on thoracic and gastrointestinal cancers - and hematologic cancers.

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

INVESTIGATIONAL THERAPY	MODALITY	INVESTIGATIONAL INDICATION	PHASE	ADDITIONAL INFORMATION
<b>Brentuximab vedotin*</b>	ADC	<i>Newly diagnosed Hodgkin lymphoma (EU)</i>	Phase 3 	Pfizer and Takeda fund joint development costs on a 50:50 basis, except in Japan where Takeda is solely responsible for development costs. Takeda has commercialization rights for the treatment outside of U.S. and Canada.
<b>Cabozantinib*</b>	Small molecule	<i>Metastatic castration-resistant prostate cancer (JP)</i>	Phase 3 	Tyrosine kinase inhibitor including MET/AXL/VEGFR Cabozantinib is being developed in Japan in collaboration with Exelixis.
<b>Fruquintinib*</b>	Small molecule	<i>Previously treated metastatic colorectal cancer (JP)</i>	Filed 	Oral VEGFR 1/2/3 tyrosine kinase inhibitor Takeda has development and commercialization rights for the treatment outside of mainland China, Hong Kong and Macau.
<b>Dazostinag (TAK-676)</b>	Small molecule	<i>Solid tumors</i>	Phase 1/2 	STING agonist
<b>Mirvetuximab soravtansine-gynx (TAK-853)</b>	ADC	<i>Folate receptor alpha (FRA)-positive ovarian cancer (JP)</i>	Phase 1/2 	Takeda has development and commercialization rights for the treatment in Japan.
<b>TAK-012</b>	Gamma delta T cell therapy	<i>Acute myeloid leukemia</i>	Phase 1/2a 	

INVESTIGATIONAL THERAPY	MODALITY	INVESTIGATIONAL INDICATION	PHASE	ADDITIONAL INFORMATION
<b>TAK-186</b>	<b>Bispecific</b>	<i>Solid tumors</i>	Phase 1/2 	EGFR x CD3 targeting COBRA (COnditional Bispecific Redirected Activation) T cell engager immunotherapy
<b>TAK-280</b>	<b>Bispecific</b>	<i>Solid tumors</i>	Phase 1/2 	B7-H3 x CD3 targeting COBRA T cell engager immunotherapy
<b>TAK-500</b>	<b>ADC</b>	<i>Solid tumors</i>	Phase 1/2 	STING agonist immunostimulatory ADC (iADC)

\*Marketed products have received approval in one or more jurisdictions.

All programs have global development rights unless otherwise noted.

GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets



@TakedaOncology

Learn more at [TakedaOncology.com](https://www.takedaoncology.com)

©2024 Takeda Pharmaceuticals U.S.A., Inc.



ONCOLOGY